Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer – PubMed
Interesting paper by Alec Zhu et al. looking at long term survival in pts with advanced urothelial cancer treated with FDA-approved ICI. We are achieving long-term survival in very few patients with advanced disease in clinical practice and we need to develop & validate biomarkers to help predict such outcomes. We also need new drugs & combos, e.g. IO+ADC, tested also in earlier (localized) stages.
PMID: 37043205
